<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03846752</url>
  </required_header>
  <id_info>
    <org_study_id>9285</org_study_id>
    <secondary_id>NL66831.075.18</secondary_id>
    <secondary_id>180716</secondary_id>
    <nct_id>NCT03846752</nct_id>
  </id_info>
  <brief_title>Complex Large-bore Radial Percutaneous Coronary Intervention (PCI) Trial</brief_title>
  <acronym>Color</acronym>
  <official_title>Complex Large-bore Radial PCI Trial Randomized Trial Reducing Access Site Complications With Slender Technology for Complex PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maatschap Cardiologie Zwolle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Terumo Europe N.V.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maatschap Cardiologie Zwolle</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The COLOR trial is a Multicenter Randomized trial. Patients are eligible for study
      participation when PCI is indicated for complex coronary lesions. If patients comply with
      inclusion and exclusion and provide written informed consent they will be randomized in a 1:1
      fashion between the two study treatments, (7 Fr. radial access with a Glideslender sheath or
      7 Fr. femoral access with a standard femoral sheath) , in a 1:1 ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The COLOR trial is a Multicenter Randomized trial. Patients are eligible for study
      participation when PCI is indicated for complex coronary lesions. If patients comply with
      inclusion and exclusion and provide written informed consent they will be randomized in a 1:1
      fashion between the two study treatments, (7 Fr. radial access with a Glideslender sheath or
      7 Fr. femoral access with a standard femoral sheath) , in a 1:1 ratio.

      During hospitalization (before discharge) the access site(s) will be checked for bleeding and
      vascular complications. All access sites should be checked for absent pulsations and
      hematomas and the size should be defined (length and width, cm) and accompanied complaints.
      Radial artery occlusion should be checked with the reverse Barbeau test. The femoral access
      site should be checked for murmurs and absence of pulsations. Ultrasound or Doppler of the
      access sites should be performed in those patients with suspected radial or femoral occlusion
      and the presence of other vascular complications, like (pseudo) aneurysms or arteriovenous
      (AV) fistula within 1 month.

      Patient-reported extremity dysfunction will be evaluated at baseline (before the procedure)
      and 1-month follow-up. Upper extremity function will be evaluated with the Quick Disabilities
      of the Arm, Shoulder and Hand questionnaire (QuickDASH) and lower extremity function with
      Lower Extremity Functional Scale questionnaire (LEFS). The occurrence of Major Adverse
      Cardiac Events (MACE) will be evaluated at discharge and 1-month follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 5, 2019</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">March 16, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is defined as BARC 2,3 and 5 (Bleeding Academic Research Consortium) bleeding or vascular complication related to the randomized access site (during hospitalization).</measure>
    <time_frame>PCI procedure till patients is discharged from the hospital, with a maximum of 30 days</time_frame>
    <description>The primary endpoint is defined as BARC 2,3 and 5 bleeding or vascular complication related to the randomized access site (during hospitalization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-access site related BARC 2,3 and 5 bleeding and/or vascular complications (hospitalization)</measure>
    <time_frame>PCI procedure till patients is discharged from the hospital, with a maximum of 30 days</time_frame>
    <description>Non-access site related BARC 2,3 and 5 bleeding and/or vascular complications (hospitalization)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE (hospitalization and 1-month)</measure>
    <time_frame>PCI procedure till 30 days after PCI procedure</time_frame>
    <description>MACE: Composite of death, myocardial infarction and repeat revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>during PCI procedure</time_frame>
    <description>Successful PCI of the target lesion with a residual stenosis of less than 20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>procedural time</measure>
    <time_frame>during PCI procedure</time_frame>
    <description>Procedural time from puncture to end procedure (in minutes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fluoroscopy time</measure>
    <time_frame>during PCI procedure</time_frame>
    <description>fluoroscopy time (in seconds)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>contrast use</measure>
    <time_frame>during PCI procedure</time_frame>
    <description>Contrast volume used (in ml)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>crossover rate</measure>
    <time_frame>during PCI procedure</time_frame>
    <description>Failure to complete the procedure through the randomized access site, requiring conversion from radial to femoral access or vice versa for procedure completion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">388</enrollment>
  <condition>Complex Coronary Lesions</condition>
  <arm_group>
    <arm_group_label>7 Fr. radial access</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radial artery access for complex PCI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7 Fr. femoral access</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>femoral artery access for complex PCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radial artery access for complex PCI</intervention_name>
    <description>Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.</description>
    <arm_group_label>7 Fr. radial access</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>femoral artery access for complex PCI</intervention_name>
    <description>Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.</description>
    <arm_group_label>7 Fr. femoral access</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Use of 7 Fr guiding catheter is indicated for complex PCI, according to the expertise
             of the treating physician.

          2. Age 18 years or older.

        Exclusion Criteria:

          1. Inability to obtain informed consent

          2. contra-indication for radial or femoral access

          3. Cardiogenic shock

          4. ST-elevation myocardial infarction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maarten A. Van Leeuwen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Isala</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charleroi</name>
      <address>
        <city>Charleroi</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost Limburg</name>
      <address>
        <city>Genk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elisabeth Krankenhaus</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OLVG</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUMC</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis Eindhoven</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RadboudUMC</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frimley Health NHS Foundation Trust, Surrey</name>
      <address>
        <city>Camberley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Transradial Intervention</keyword>
  <keyword>transfemoral intervention</keyword>
  <keyword>PCI for complex coronary lesions</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The availability of individual participant data will be separately decided for each request by the PI of the study. The sponsor will have to agree before publication.
All data that is required to minimally fulfill the request will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data is available after publication of final specific subgroup analyses, no predetermined end-date</ipd_time_frame>
    <ipd_access_criteria>Proposals should be directed to the PI of the study (m.a.h.van.leeuwen@isala.nl). To gain access, data requestors will need to sign a data transfer agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

